Dupilumab for the treatment of recalcitrant eosinophilic dermatosis of haematologic malignancy
J Eur Acad Dermatol Venereol
.
2021 Aug;35(8):e501-e503.
doi: 10.1111/jdv.17232.
Epub 2021 Mar 28.
Authors
R Maglie
1
,
F Ugolini
2
,
F De Logu
3
,
S Simi
2
,
S Senatore
1
,
F Montefusco
1
,
R Nassini
3
,
D Massi
2
,
E Antiga
1
Affiliations
1
Department of Health Sciences, Section of Dermatology, University of Florence, Florence, Italy.
2
Department of Health Sciences, Section of Pathological Anatomy, University of Florence, Florence, Italy.
3
Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Florence, Italy.
PMID:
33730368
DOI:
10.1111/jdv.17232
No abstract available
Publication types
Letter
MeSH terms
Antibodies, Monoclonal, Humanized
Hematologic Neoplasms*
Humans
Leukemia, Lymphocytic, Chronic, B-Cell*
Skin Diseases*
Substances
Antibodies, Monoclonal, Humanized
dupilumab